PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome

Poor clinical outcome of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has been attributed to failure of current chemotherapeutic regimens to target leukemic stem cells. We recently identified p21-activated kinase (PAK1) as a downstream effector molecule of H2.0-like homeobox (HLX)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Pandolfi, Ashley, Stanley, Robert F., Yu, Yiting, Bartholdy, Boris, Pendurti, Gopichand, Gritsman, Kira, Boultwood, Jacqueline, Chernoff, Jonathan, Verma, Amit, Steidl, Ulrich
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2015
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4551362/
https://ncbi.nlm.nih.gov/pubmed/26170031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-12-618801
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados